Literature DB >> 23796410

Understanding and altering cell tropism of vesicular stomatitis virus.

Eric Hastie1, Marcela Cataldi, Ian Marriott, Valery Z Grdzelishvili.   

Abstract

Vesicular stomatitis virus (VSV) is a prototypic nonsegmented negative-strand RNA virus. VSV's broad cell tropism makes it a popular model virus for many basic research applications. In addition, a lack of preexisting human immunity against VSV, inherent oncotropism and other features make VSV a widely used platform for vaccine and oncolytic vectors. However, VSV's neurotropism that can result in viral encephalitis in experimental animals needs to be addressed for the use of the virus as a safe vector. Therefore, it is very important to understand the determinants of VSV tropism and develop strategies to alter it. VSV glycoprotein (G) and matrix (M) protein play major roles in its cell tropism. VSV G protein is responsible for VSV broad cell tropism and is often used for pseudotyping other viruses. VSV M affects cell tropism via evasion of antiviral responses, and M mutants can be used to limit cell tropism to cell types defective in interferon signaling. In addition, other VSV proteins and host proteins may function as determinants of VSV cell tropism. Various approaches have been successfully used to alter VSV tropism to benefit basic research and clinically relevant applications.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Host factors; Neurotoxicity; Neurotropism; Oncolytic; Tropism; VSV; Vesicular stomatitis virus

Mesh:

Substances:

Year:  2013        PMID: 23796410      PMCID: PMC3865924          DOI: 10.1016/j.virusres.2013.06.003

Source DB:  PubMed          Journal:  Virus Res        ISSN: 0168-1702            Impact factor:   3.303


  259 in total

1.  Leukotrienes play protective roles early during experimental VSV encephalitis.

Authors:  N Chen; A Restivo; C S Reiss
Journal:  J Neuroimmunol       Date:  2001-11-01       Impact factor: 3.478

2.  Enhanced oncolytic activity of vesicular stomatitis virus encoding SV5-F protein against prostate cancer.

Authors:  Guimin Chang; Shuping Xu; Makiko Watanabe; Himangi R Jayakar; Michael A Whitt; Jeffrey R Gingrich
Journal:  J Urol       Date:  2010-02-20       Impact factor: 7.450

3.  RIG-I detects viral genomic RNA during negative-strand RNA virus infection.

Authors:  Jan Rehwinkel; Choon Ping Tan; Delphine Goubau; Oliver Schulz; Andreas Pichlmair; Katja Bier; Nicole Robb; Frank Vreede; Wendy Barclay; Ervin Fodor; Caetano Reis e Sousa
Journal:  Cell       Date:  2010-02-05       Impact factor: 41.582

4.  Unconventional mechanism of mRNA capping by the RNA-dependent RNA polymerase of vesicular stomatitis virus.

Authors:  Tomoaki Ogino; Amiya K Banerjee
Journal:  Mol Cell       Date:  2007-01-12       Impact factor: 17.970

5.  Endosome-to-cytosol transport of viral nucleocapsids.

Authors:  Isabelle Le Blanc; Pierre-Philippe Luyet; Véronique Pons; Charles Ferguson; Neil Emans; Anne Petiot; Nathalie Mayran; Nicolas Demaurex; Julien Fauré; Rémy Sadoul; Robert G Parton; J Gruenberg
Journal:  Nat Cell Biol       Date:  2005-06-12       Impact factor: 28.824

Review 6.  Vesicular stomatitis virus as an oncolytic vector.

Authors:  Glen N Barber
Journal:  Viral Immunol       Date:  2004       Impact factor: 2.257

7.  Effect of erythrocyte transbilayer phospholipid distribution on fusion with vesicular stomatitis virus.

Authors:  A Herrmann; M J Clague; A Puri; S J Morris; R Blumenthal; S Grimaldi
Journal:  Biochemistry       Date:  1990-05-01       Impact factor: 3.162

8.  Phosphorylation by cellular casein kinase II is essential for transcriptional activity of vesicular stomatitis virus phosphoprotein P.

Authors:  S Barik; A K Banerjee
Journal:  Proc Natl Acad Sci U S A       Date:  1992-07-15       Impact factor: 11.205

9.  Semireplication-competent vesicular stomatitis virus as a novel platform for oncolytic virotherapy.

Authors:  Alexander Muik; Catherine Dold; Yvonne Geiß; Andreas Volk; Marina Werbizki; Ursula Dietrich; Dorothee von Laer
Journal:  J Mol Med (Berl)       Date:  2012-08       Impact factor: 4.599

10.  The effects of N-terminal insertion into VSV-G of an scFv peptide.

Authors:  Hanna Dreja; Marc Piechaczyk
Journal:  Virol J       Date:  2006-09-02       Impact factor: 4.099

View more
  45 in total

1.  Robust kinetics of an RNA virus: Transcription rates are set by genome levels.

Authors:  Collin Timm; Ankur Gupta; John Yin
Journal:  Biotechnol Bioeng       Date:  2015-05-20       Impact factor: 4.530

2.  Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe.

Authors:  Selidji T Agnandji; Angela Huttner; Madeleine E Zinser; Patricia Njuguna; Christine Dahlke; José F Fernandes; Sabine Yerly; Julie-Anne Dayer; Verena Kraehling; Rahel Kasonta; Akim A Adegnika; Marcus Altfeld; Floriane Auderset; Emmanuel B Bache; Nadine Biedenkopf; Saskia Borregaard; Jessica S Brosnahan; Rebekah Burrow; Christophe Combescure; Jules Desmeules; Markus Eickmann; Sarah K Fehling; Axel Finckh; Ana Rita Goncalves; Martin P Grobusch; Jay Hooper; Alen Jambrecina; Anita L Kabwende; Gürkan Kaya; Domtila Kimani; Bertrand Lell; Barbara Lemaître; Ansgar W Lohse; Marguerite Massinga-Loembe; Alain Matthey; Benjamin Mordmüller; Anne Nolting; Caroline Ogwang; Michael Ramharter; Jonas Schmidt-Chanasit; Stefan Schmiedel; Peter Silvera; Felix R Stahl; Henry M Staines; Thomas Strecker; Hans C Stubbe; Benjamin Tsofa; Sherif Zaki; Patricia Fast; Vasee Moorthy; Laurent Kaiser; Sanjeev Krishna; Stephan Becker; Marie-Paule Kieny; Philip Bejon; Peter G Kremsner; Marylyn M Addo; Claire-Anne Siegrist
Journal:  N Engl J Med       Date:  2015-04-01       Impact factor: 91.245

Review 3.  Trans-synaptic Neural Circuit-Tracing with Neurotropic Viruses.

Authors:  Jiamin Li; Taian Liu; Yun Dong; Kunio Kondoh; Zhonghua Lu
Journal:  Neurosci Bull       Date:  2019-04-19       Impact factor: 5.203

4.  Recent advances in vesicular stomatitis virus-based oncolytic virotherapy: a 5-year update.

Authors:  Sébastien A Felt; Valery Z Grdzelishvili
Journal:  J Gen Virol       Date:  2017-12       Impact factor: 3.891

Review 5.  Rhabdoviruses as vectors for vaccines and therapeutics.

Authors:  Gabrielle Scher; Matthias J Schnell
Journal:  Curr Opin Virol       Date:  2020-10-29       Impact factor: 7.090

6.  Mechanisms of Innate Immune Activation by a Hybrid Alphavirus-Rhabdovirus Vaccine Platform.

Authors:  Anthony M Marchese; Carolina Chiale; Safiehkhatoon Moshkani; Michael D Robek
Journal:  J Interferon Cytokine Res       Date:  2019-10-18       Impact factor: 2.607

7.  Safety Studies in Tumor and Non-Tumor-Bearing Mice in Support of Clinical Trials Using Oncolytic VSV-IFNβ-NIS.

Authors:  Lianwen Zhang; Michael B Steele; Nathan Jenks; Jacquelyn Grell; Lukkana Suksanpaisan; Shruthi Naik; Mark J Federspiel; Martha Q Lacy; Stephen J Russell; Kah-Whye Peng
Journal:  Hum Gene Ther Clin Dev       Date:  2016-09       Impact factor: 5.032

8.  Ruxolitinib and Polycation Combination Treatment Overcomes Multiple Mechanisms of Resistance of Pancreatic Cancer Cells to Oncolytic Vesicular Stomatitis Virus.

Authors:  Sébastien A Felt; Gaith N Droby; Valery Z Grdzelishvili
Journal:  J Virol       Date:  2017-07-27       Impact factor: 5.103

Review 9.  Everything You Always Wanted to Know About Rabies Virus (But Were Afraid to Ask).

Authors:  Benjamin M Davis; Glenn F Rall; Matthias J Schnell
Journal:  Annu Rev Virol       Date:  2015-06-24       Impact factor: 10.431

10.  Breaking resistance of pancreatic cancer cells to an attenuated vesicular stomatitis virus through a novel activity of IKK inhibitor TPCA-1.

Authors:  Marcela Cataldi; Nirav R Shah; Sébastien A Felt; Valery Z Grdzelishvili
Journal:  Virology       Date:  2015-08-29       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.